ANB 019

Drug Profile

ANB 019

Alternative Names: ANB019

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Immunotherapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pustular psoriasis

Most Recent Events

  • 06 Nov 2017 Interim adverse events, pharmacokinetics and pharmacodynamics efficacy data from a phase I trial in Healthy volunteers released by AnaptysBio
  • 06 Apr 2017 Phase-I clinical trials in Pustular psoriasis in Australia (SC and IV)
  • 06 Apr 2017 AnaptysBio plans phase II trials for Pustular psoriasis and Palmoplantar pustular psoriasis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top